Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators

Authors: Michal L Melamed, Laura Plantinga, Tariq Shafi, Rulan Parekh, Timothy W Meyer, Thomas H Hostetter, Josef Coresh, Neil R Powe

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Multiple solutes are retained in uremia, but it is currently unclear which solutes are toxic. Small studies suggest that protein-bound solutes, such as p-cresol sulfate and indoxyl sulfate and intracellular solutes, such as methylamine (MMA) and dimethylamine (DMA), may be toxic. Our objective was to test whether elevated levels of these solutes were associated with mortality.

Methods

We conducted a prospective cohort study in 521 U.S. incident hemodialysis patients to evaluate associations between these solutes and all-cause and cardiovascular mortality. P-cresol sulfate, indoxyl sulfate, MMA and DMA levels were measured from frozen plasma samples obtained 2 to 6 months after initiation of dialysis. Mortality data was available through 2004 using the National Death Index.

Results

Elevated (greater than the population median) p-cresol sulfate, MMA or DMA levels were not associated with all-cause or cardiovascular mortality. Elevated indoxyl sulfate levels were associated with all-cause mortality but not cardiovascular mortality (hazard ratio 1.30 (95% confidence interval 1.01, 1.69) p-value 0.043).

Conclusions

In this cohort of 521 incident hemodialysis patients, only elevated indoxyl sulfate levels were associated with all-cause mortality. Further research is needed to identify causes of the toxicity of uremia to provide better care for patients with kidney disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference United States Renal Data System: USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. 2011, Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases United States Renal Data System: USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. 2011, Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases
2.
go back to reference Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998, 9: S16-S23.PubMed Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998, 9: S16-S23.PubMed
3.
go back to reference de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al: Cardiovascular and noncardiovascular mortality among patients starting dialysis. Jama. 2009, 302: 1782-1789. 10.1001/jama.2009.1488.CrossRefPubMed de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al: Cardiovascular and noncardiovascular mortality among patients starting dialysis. Jama. 2009, 302: 1782-1789. 10.1001/jama.2009.1488.CrossRefPubMed
4.
go back to reference Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008, 19: 863-870. 10.1681/ASN.2007121377.CrossRefPubMed Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008, 19: 863-870. 10.1681/ASN.2007121377.CrossRefPubMed
5.
go back to reference Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol JASN. 2012, 23: 1258-1270. 10.1681/ASN.2011121175.CrossRefPubMed Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol JASN. 2012, 23: 1258-1270. 10.1681/ASN.2011121175.CrossRefPubMed
6.
go back to reference Meyer TW, Walther JL, Pagtalunan ME, Martinez AW, Torkamani A, Fong PD, et al: The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int. 2005, 68: 867-877. 10.1111/j.1523-1755.2005.00469.x.CrossRefPubMed Meyer TW, Walther JL, Pagtalunan ME, Martinez AW, Torkamani A, Fong PD, et al: The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int. 2005, 68: 867-877. 10.1111/j.1523-1755.2005.00469.x.CrossRefPubMed
7.
go back to reference Ponda MP, Quan Z, Melamed ML, Raff A, Meyer TW, Hostetter TH: Methylamine clearance by haemodialysis is low. Nephrol Dial Transplant. 2010, 25: 1608-1613. 10.1093/ndt/gfp629.CrossRefPubMed Ponda MP, Quan Z, Melamed ML, Raff A, Meyer TW, Hostetter TH: Methylamine clearance by haemodialysis is low. Nephrol Dial Transplant. 2010, 25: 1608-1613. 10.1093/ndt/gfp629.CrossRefPubMed
8.
go back to reference Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH: Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010, 25: 3693-3700. 10.1093/ndt/gfq251.CrossRefPubMed Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH: Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010, 25: 3693-3700. 10.1093/ndt/gfq251.CrossRefPubMed
9.
go back to reference Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009, 4: 1551-1558. 10.2215/CJN.03980609.CrossRefPubMedPubMedCentral Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009, 4: 1551-1558. 10.2215/CJN.03980609.CrossRefPubMedPubMedCentral
10.
go back to reference Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al: Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010, 25: 1183-1191. 10.1093/ndt/gfp592.CrossRefPubMed Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al: Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010, 25: 1183-1191. 10.1093/ndt/gfp592.CrossRefPubMed
11.
go back to reference Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al: P-cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. 2010, 5: 1182-1189. 10.2215/CJN.07971109.CrossRefPubMedPubMedCentral Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al: P-cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. 2010, 5: 1182-1189. 10.2215/CJN.07971109.CrossRefPubMedPubMedCentral
12.
go back to reference Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients–protein-bound uremic toxins and endothelial dysfunction. Semin Dial. 2011, 24: 327-337. 10.1111/j.1525-139X.2011.00925.x.CrossRefPubMed Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients–protein-bound uremic toxins and endothelial dysfunction. Semin Dial. 2011, 24: 327-337. 10.1111/j.1525-139X.2011.00925.x.CrossRefPubMed
13.
go back to reference Pirisino R, Ghelardini C, Pacini A, Galeotti N, Raimondi L: Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain kv1.6 channel subtype. Br J Pharmacol. 2004, 142: 381-389. 10.1038/sj.bjp.0705740.CrossRefPubMedPubMedCentral Pirisino R, Ghelardini C, Pacini A, Galeotti N, Raimondi L: Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain kv1.6 channel subtype. Br J Pharmacol. 2004, 142: 381-389. 10.1038/sj.bjp.0705740.CrossRefPubMedPubMedCentral
14.
go back to reference Pirisino R, Ghelardini C, Banchelli G, Galeotti N, Raimondi L: Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aodn towards kv1.1 channels. Br J Pharmacol. 2001, 134: 880-886. 10.1038/sj.bjp.0704316.CrossRefPubMedPubMedCentral Pirisino R, Ghelardini C, Banchelli G, Galeotti N, Raimondi L: Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aodn towards kv1.1 channels. Br J Pharmacol. 2001, 134: 880-886. 10.1038/sj.bjp.0704316.CrossRefPubMedPubMedCentral
15.
go back to reference Raimondi L, Alfarano C, Pacini A, Livi S, Ghelardini C, DeSiena G, et al: Methylamine-dependent release of nitric oxide and dopamine in the cns modulates food intake in fasting rats. Br J Pharmacol. 2007, 150: 1003-1010.CrossRefPubMedPubMedCentral Raimondi L, Alfarano C, Pacini A, Livi S, Ghelardini C, DeSiena G, et al: Methylamine-dependent release of nitric oxide and dopamine in the cns modulates food intake in fasting rats. Br J Pharmacol. 2007, 150: 1003-1010.CrossRefPubMedPubMedCentral
16.
go back to reference Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. Jama. 2004, 291: 451-459. 10.1001/jama.291.4.451.CrossRefPubMed Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. Jama. 2004, 291: 451-459. 10.1001/jama.291.4.451.CrossRefPubMed
17.
go back to reference Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol. 2005, 16: 3430-3436. 10.1681/ASN.2005030310.CrossRefPubMed Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol. 2005, 16: 3430-3436. 10.1681/ASN.2005030310.CrossRefPubMed
18.
go back to reference Quan ZPM, Melamed M, Raff A, Berman N, Scherer J, Bitzer M, Meyer T, Hostetter TH: Derivitization of methylamine and ethylamine followed by lc and fluorescence detection for measurement of urinary clearance. Chromatographia. 2010, 71: 411-10.1365/s10337-009-1464-6.CrossRef Quan ZPM, Melamed M, Raff A, Berman N, Scherer J, Bitzer M, Meyer T, Hostetter TH: Derivitization of methylamine and ethylamine followed by lc and fluorescence detection for measurement of urinary clearance. Chromatographia. 2010, 71: 411-10.1365/s10337-009-1464-6.CrossRef
19.
go back to reference Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al: Relationship of c-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol. 1997, 17: 1121-1127. 10.1161/01.ATV.17.6.1121.CrossRefPubMed Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al: Relationship of c-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol. 1997, 17: 1121-1127. 10.1161/01.ATV.17.6.1121.CrossRefPubMed
20.
go back to reference Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, et al: Comparison of causes of death using hemo study and hcfa end-stage renal disease death notification classification systems. The National Institutes of Health-Funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis. 2002, 39: 146-153. 10.1053/ajkd.2002.29905.CrossRefPubMed Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, et al: Comparison of causes of death using hemo study and hcfa end-stage renal disease death notification classification systems. The National Institutes of Health-Funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis. 2002, 39: 146-153. 10.1053/ajkd.2002.29905.CrossRefPubMed
21.
go back to reference Miskulin DC, Martin AA, Brown R, Fink NE, Coresh J, Powe NR, et al: Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant. 2004, 19: 413-420. 10.1093/ndt/gfg571.CrossRefPubMed Miskulin DC, Martin AA, Brown R, Fink NE, Coresh J, Powe NR, et al: Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant. 2004, 19: 413-420. 10.1093/ndt/gfg571.CrossRefPubMed
22.
23.
go back to reference Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer TW: Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis. 2009, 53: 1042-1049. 10.1053/j.ajkd.2009.01.265.CrossRefPubMed Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer TW: Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis. 2009, 53: 1042-1049. 10.1053/j.ajkd.2009.01.265.CrossRefPubMed
24.
go back to reference Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006, 69: 1081-1087. 10.1038/sj.ki.5000115.CrossRefPubMed Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006, 69: 1081-1087. 10.1038/sj.ki.5000115.CrossRefPubMed
25.
go back to reference Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, et al: Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease. Nephrologie therapeutique. 2011, 7: 219-224.CrossRefPubMed Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, et al: Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease. Nephrologie therapeutique. 2011, 7: 219-224.CrossRefPubMed
26.
go back to reference Rocco MV, Lockridge RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, et al: The effects of frequent nocturnal home hemodialysis: the frequent hemodialysis network nocturnal trial. Kidney Int. 2011, 80: 1080-1091. 10.1038/ki.2011.213.CrossRefPubMedPubMedCentral Rocco MV, Lockridge RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, et al: The effects of frequent nocturnal home hemodialysis: the frequent hemodialysis network nocturnal trial. Kidney Int. 2011, 80: 1080-1091. 10.1038/ki.2011.213.CrossRefPubMedPubMedCentral
27.
go back to reference Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al: In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010, 363: 2287-2300.CrossRefPubMed Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al: In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010, 363: 2287-2300.CrossRefPubMed
Metadata
Title
Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators
Authors
Michal L Melamed
Laura Plantinga
Tariq Shafi
Rulan Parekh
Timothy W Meyer
Thomas H Hostetter
Josef Coresh
Neil R Powe
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-134

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.